| Strain Name |
C57BL/6-Il31tm1(IL31)Bcgen Il31ratm1(IL31RA)Bcgen Osmrtm1(OSMR)Bcgen Il4tm2(IL4)Bcgen Il4ratm1(IL4RA)Bcgen/Bcgen |
Common Name | B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice |
| Background | C57BL/6 | Catalog number | 112908 |
|
Related Genes |
CD124, IL-4RAA, IL4R; CRL, CRL3, GLM-R, GLMR, GPL, IL-31RA, PLCA2, PRO21384, hGLM-R; BCGF-1, BCGF1, BSF-1, BSF1, IL-4 |
||
Strain specific IL4RA expression analysis in homozygous B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice stimulated with LPS (200 μg/mice, i.p.) for 2 h, and analyzed by flow cytometry with anti-mouse IL4RA antibody (Biolegend, 144803) or anti-human IL4RA antibody (Biolegend, 355005). Mouse IL4RA was only detectable in wild-type mice, while hIL4RA was exclusively detectable in homozygous mice.
Efficacy evaluation of bispecific antibody in AD model of B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA
Efficacy evaluation of bispecific antibody in AD model of B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice. A. OXA was applied to dorsal and ear skin of B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice (female, 8-week-old, n=6) on day 0, and then challenge to the same site of skin nine times from days 7 to 25. Dupilumab, bispecific antibody (BsAb) (Dupilumab, or BsAb provided by client) were intraperitoneally injected in G3-G7. Ear tissues and serum were collected at the endpoint on day 26. B. Ear thickness. C. Ear thickness change. Scratching behavior was recorded on day 11 (D), day 23 (E). F. Day 16 Serum-Total IgE. G. Day 26 Serum-Total IgE. The results showed that ear thicknesses and serum IgE levels were decreased in TA1,TA2,TA3, and Dupilumab with or without TA4 treated group. The combination of Dupilumab and TA4 significantly attenuates scratching behaviors on day 11. The data is expressed as mean ± SEM (* p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001). AD: atopic dermatitis; OXA: oxazolone.
Note: This experiment is a collaboration with the client.
Efficacy evaluation of bispecific antibody in AD model of B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice. A. Hematoxylin and eosin (H&E) staining. B. Total pathological score. C. Epidermal thickness. D. Eosinophil score. Ear thickness and infiltration scores of eosinophils in ear skin of the groups treated with TA1,TA2 and Dupilumab analog with or without TA4 were decreased significantly compared to that in the isotype control, demonstrating that the B-hIL31/hIL31RA/hOSMR/hIL4/hIL4RA mice provide a powerful preclinical model for in vivo evaluation of bispecific antibody. Infiltration score of eosinophils: 1=slight; 2=mild; 3=moderate; 4=severe. The content of the pathology total score evaluation includes the following aspects: epidermal hyperplasia in skin, erosion/crusting, hyperkeratosis and parakeratosis; inflammatory cell infiltration in dermis and subcutaneous. The data is expressed as mean ± SEM (* p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, n.s. no significance).
Note: This experiment is a collaboration with the client.
京公网安备：